Dr. Sances leads insitro's ALS program in collaboration with BMS, utilizing scalable iPSC techniques, automation, and machine learning to discover new therapeutic targets. His expertise in modeling neurodegeneration and target discovery began as a CIRM fellow in La Jolla and further developed at Cedars-Sinai, where he designed in vitro models of sporadic ALS using organ chip systems to replicate complex tissue interactions. Throughout his career, Dr. Sances has focused on using advanced bioengineering and computational tools to deepen the understanding of ALS and develop transformative treatments for patients.